Literature DB >> 22583811

Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats.

M Pravetoni1, M D Raleigh, M Le Naour, A M Tucker, T M Harmon, J M Jones, A K Birnbaum, P S Portoghese, P R Pentel.   

Abstract

Opioid conjugate vaccines have shown promise in animal models as a potential treatment for opioid addiction. Individual vaccines are quite specific and each targets only a limited number of structurally similar opioids. Since opioid users can switch or transition between opioids, we studied a bivalent immunization strategy of combining 2 vaccines that could target several of the most commonly abused opioids; heroin, oxycodone and their active metabolites. Morphine (M) and oxycodone (OXY) haptens were conjugated to keyhole limpet hemocyanin (KLH) through tetraglycine (Gly)(4) linkers at the C6 position. Immunization of rats with M-KLH alone produced high titers of antibodies directed against heroin, 6-monoacetylmorphine (6-MAM) and morphine. Immunization with OXY-KLH produced high titers of antibodies against oxycodone and oxymorphone. Immunization with the bivalent vaccine produced consistently high antibody titers against both immunogens. Bivalent vaccine antibody titers against the individual immunogens were higher than with the monovalent vaccines alone owing, at least in part, to cross-reactivity of the antibodies. Administration of a single concurrent intravenous dose of 6-MAM and oxycodone to rats immunized with the bivalent vaccine increased 6-MAM, morphine and oxycodone retention in serum and reduced the distribution of 6-MAM and oxycodone to brain. Vaccine efficacy correlated with serum antibody titers for both monovalent vaccines, alone or in combination. Efficacy of the individual vaccines was not compromised by their combined use. Consistent with the enhanced titers in the bivalent group, a trend toward enhanced pharmacokinetic efficacy with the bivalent vaccine was observed. These data support the possibility of co-administering two or more opioid vaccines concurrently to target multiple abusable opioids without compromising the immunogenicity or efficacy of the individual components.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22583811      PMCID: PMC3372705          DOI: 10.1016/j.vaccine.2012.04.101

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

Review 1.  Major increases in opioid analgesic abuse in the United States: concerns and strategies.

Authors:  Wilson M Compton; Nora D Volkow
Journal:  Drug Alcohol Depend       Date:  2005-07-14       Impact factor: 4.492

Review 2.  Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors.

Authors:  Benito Anton; Alberto Salazar; Anabel Flores; Maura Matus; Rodrigo Marin; Jorge-Alberto Hernandez; Philippe Leff
Journal:  Hum Vaccin       Date:  2009-04-08

3.  The prescription drug epidemic in the United States: a perfect storm.

Authors:  Jane Carlisle Maxwell
Journal:  Drug Alcohol Rev       Date:  2011-05

Review 4.  Prescription pain medication dependence.

Authors:  Carrie L Dodrill; Drew A Helmer; Thomas R Kosten
Journal:  Am J Psychiatry       Date:  2011-05       Impact factor: 18.112

5.  Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat.

Authors:  M I Bazin-Redureau; C B Renard; J M Scherrmann
Journal:  J Pharm Pharmacol       Date:  1997-03       Impact factor: 3.765

6.  Influence of active and passive immunity on the disposition of dihydromorphine-H3.

Authors:  B A Berkowitz; K V Ceretta; S Spector
Journal:  Life Sci       Date:  1974-09-01       Impact factor: 5.037

7.  Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities.

Authors:  M Pravetoni; D E Keyler; R R Pidaparthi; F I Carroll; S P Runyon; M P Murtaugh; C A Earley; P R Pentel
Journal:  Biochem Pharmacol       Date:  2011-11-15       Impact factor: 5.858

8.  A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents.

Authors:  Benito Anton; Philippe Leff
Journal:  Vaccine       Date:  2006-02-08       Impact factor: 3.641

9.  Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans.

Authors:  Margaret Haney; Erik W Gunderson; Huiping Jiang; Eric D Collins; Richard W Foltin
Journal:  Biol Psychiatry       Date:  2010-01-01       Impact factor: 13.382

10.  Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic.

Authors:  D K Hatsukami; D E Jorenby; D Gonzales; N A Rigotti; E D Glover; C A Oncken; D P Tashkin; V I Reus; R C Akhavain; R E F Fahim; P D Kessler; M Niknian; M W Kalnik; S I Rennard
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

View more
  42 in total

1.  Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum.

Authors:  Sabina H L de Villiers; Katherine E Cornish; Andrew J Troska; Marco Pravetoni; Paul R Pentel
Journal:  Vaccine       Date:  2013-10-29       Impact factor: 3.641

2.  A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats.

Authors:  Michael D Raleigh; Federico Baruffaldi; Samantha J Peterson; Morgan Le Naour; Theresa M Harmon; Jennifer R Vigliaturo; Paul R Pentel; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2018-11-08       Impact factor: 4.030

3.  Dynamic vaccine blocks relapse to compulsive intake of heroin.

Authors:  Joel E Schlosburg; Leandro F Vendruscolo; Paul T Bremer; Jonathan W Lockner; Carrie L Wade; Ashlee A K Nunes; G Neil Stowe; Scott Edwards; Kim D Janda; George F Koob
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

Review 4.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

Review 5.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

6.  Efficacious Vaccine against Heroin Contaminated with Fentanyl.

Authors:  Candy S Hwang; Lauren C Smith; Yoshihiro Natori; Beverly Ellis; Bin Zhou; Kim D Janda
Journal:  ACS Chem Neurosci       Date:  2018-03-23       Impact factor: 4.418

7.  Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats.

Authors:  M D Raleigh; M Pravetoni; A C Harris; A K Birnbaum; P R Pentel
Journal:  J Pharmacol Exp Ther       Date:  2012-12-07       Impact factor: 4.030

8.  Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse.

Authors:  J J Taylor; M Laudenbach; A M Tucker; M K Jenkins; M Pravetoni
Journal:  J Immunol Methods       Date:  2014-01-23       Impact factor: 2.303

9.  Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens.

Authors:  Marco Pravetoni; Morgan Le Naour; Ashli M Tucker; Theresa M Harmon; Tara M Hawley; Philip S Portoghese; Paul R Pentel
Journal:  J Med Chem       Date:  2013-01-15       Impact factor: 7.446

10.  Synthesis and immunological effects of heroin vaccines.

Authors:  Fuying Li; Kejun Cheng; Joshua F G Antoline; Malliga R Iyer; Gary R Matyas; Oscar B Torres; Rashmi Jalah; Zoltan Beck; Carl R Alving; Damon A Parrish; Jeffrey R Deschamps; Arthur E Jacobson; Kenner C Rice
Journal:  Org Biomol Chem       Date:  2014-10-07       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.